Skip to main content
. Author manuscript; available in PMC: 2022 Apr 5.
Published in final edited form as: Cancer Cell. 2021 Jul 21;39(8):1115–1134.e12. doi: 10.1016/j.ccell.2021.06.016

Figure 8. ITGAV/ITGB5 are effectors of YAP-induced cytostasis.

Figure 8.

(A) Scatterplot of fold difference between YAP- and empty vector-transduced or input cells for each single-guide RNA in the CRISPR screen.

(B) ITGB5 knockout rescues YAP-induced cytostasis.

(C) Western blots in YAP-transduced YAPoff or YAP/TAZ-knockout YAPon lines.

(D) Knockout of ITGAV, but not other integrins, alleviates YAP-induced cytostasis.

(E) ITGAV/B5, but not ITGB1, blocking antibody alleviates YAP-induced cytostasis. All panels: mean ± SD, n ≥ 3. *p < 0.05, **p < 0.01, ***p < 0.001 versus singleguide control or untreated (untr) cells.

(F) Cyclic RGD peptide (cRGD) blocks YAP-induced adhesion (images), but not cytostasis (graphs). Scale bars, 200 µm.

(G) Summary of contrasting YAP/TEAD mechanisms of action in solid YAPon and YAPoff cancers.

See also Figure S8.